CA-HALIO
16.11.2023 14:01:35 CET | Business Wire | Press release
HALIO, designer of the world’s fastest, most beautiful, eco-friendly, and technologically advanced electrochromic (smart) glass, and SKC Ltd., a leading company in the ESG Materials Solution industry based in South Korea, today announced that HALIO has raised up to $70M in funding from SKC to further market and develop the industry’s next generation of smart glass technology, focusing on energy savings, environmental impact, and creating beautiful facades, while enabling occupant wellness and comfort.
“This investment is expected to further expand our ESG strategy,” said SKC’s Vice President Junghwan Shin. “We strongly believe that HALIO has the most advanced smart glass technology that will significantly impact global energy savings and our environment,” emphasized Shin.
In conjunction with the funding announcement, HALIO also announced the appointment of Doug Schendt as the company's new CEO, replacing Bruce Sohn, who has served as CEO since 2020. Sohn is retiring after successfully leading the company through this latest milestone.
"I'm thrilled to take on this new role and lead HALIO into its next phase of growth," said Schendt. "Having previously led our Asia operations, I'm excited to now head HALIO globally. Bruce's vision and leadership have positioned us well, and I look forward to building on that strong foundation."
HALIO Smart Glass enables architects to design beautiful and elegant facades, supporting building owners’ pursuit of providing occupants with the most comfortable, productive, and healthy interior environments. HALIO’s Sky Camera, tint algorithms, and control automation, coupled with the industry’s fastest switching speed (within seconds), make HALIO the only smart glass solution that truly optimizes daylight control and solar heat gain management in real-time.
HALIO's smart glass technology reduces a building's operational energy use by up to 22%. It decreases peak demand by 25%, which is vital in balancing overstressed power grids (Red Car Analytics - Energy Efficiency Analysis of HALIO, Nov 2019). With countries now targeting buildings as major energy users, regulations increasingly require more efficient facades. Additionally, new incentives like the U.S. Investment Tax Credit reward owners for adding energy-saving solutions like HALIO Smart Glass.
"This new capital enables us to accelerate innovation in our smart glass technology as well as expand our reach in key markets like Asia, Europe, and the Middle East," added Sohn. "This is an incredibly exciting time for HALIO. I'm proud of what we've accomplished and am confident that with Doug as CEO, the company is in great hands to continue our mission and bring our products to customers globally."
About HALIO
HALIO Smart Glass is the world’s fastest and most advanced electrochromic (smart glass) technology, enabling maximum control of daylight while optimizing energy savings by reducing solar heat gain and minimizing glare. Powered by HALIO windows and skylights are available directly from the HALIO and third-party fabricators, including Viracon and GLASSBEL, with various glass coatings and configurations. Beautiful buildings deserve beautiful facades. Find out more what HALIO can do for your next building project at www.halioinc.com.
About SKC
For the past 40 years, SKC has focused on developing materials to create a better world, positioning today as a ‘Materials Solution Company’. SKC has recently reorganized its business portfolio, centering around rechargeable batteries, semiconductors, and eco-friendly materials. Our goal is to provide new values to customers with state-of-the-art technology and earn support and trust from both customers and society, with the vision of becoming a ‘Global Major ESG Eco-Friendly Materials Solution Company’. SKC will continue to make ceaseless challenge and innovation. Learn more: http://www.skc.co.kr/eng/main/index.do
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116891065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom